Department of Infectious Diseases, Toranomon Hospital.
Department of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Japan.
Clin Infect Dis. 2018 Aug 1;67(4):573-578. doi: 10.1093/cid/ciy114.
Previous studies suggest that Helicobacter cinaedi can cause recurrent bacteremia. In this study, we elucidated the risk factors for recurrent H. cinaedi bacteremia and explored the efficacy of selective digestive decontamination (SDD) as a preventive measure.
We retrospectively reviewed the medical records of patients with H. cinaedi bacteremia between March 2009 and December 2016 at 2 Japanese hospitals.
We identified 168 patients with H. cinaedi bacteremia. Bacteremia recurred in 34 patients. The 100-day cumulative incidence rate of recurrent bacteremia was 18.7%. In univariate analysis of factors associated with recurrent bacteremia, anticancer chemotherapy (hazard ratio [HR], 3.75; 95% confidence interval [CI], 1.86-7.58; P < .001), systemic steroids (HR, 3.79; 95% CI, 1.70-8.45; P = .0011), and hematological malignancy (HR, 3.18; 95% CI, 1.64-6.19; P < .001) were detected. Multivariate analysis indicated that anticancer chemotherapy (HR, 2.47; 95% CI, 1.19-5.12; P = .015) and systemic steroids (HR, 2.40; 95% CI, 1.03-5.61; P = .044) were the independent risk factors. Of the 168 patients, 47 received SDD. According to Gray's test, SDD might have reduced the rate of recurrence but this was not statistically significant (HR, 0.46; 95% CI, 0.18-1.18; P = .11). However, in a proportional hazard modeling analysis, SDD reduced the rate of recurrence (HR, 0.36; 95% CI, 0.13-1.00; P = .050).
The 100-day cumulative incidence of recurrent H. cinaedi bacteremia was 18.7%. Anticancer chemotherapy and systemic steroids were independent risk factors for recurrent bacteremia. SDD is a potential strategy for reducing the recurrence.
先前的研究表明,脆弱拟杆菌可引起复发性菌血症。在本研究中,我们阐明了复发性脆弱拟杆菌菌血症的危险因素,并探讨了选择性消化道去污染(SDD)作为预防措施的效果。
我们回顾性分析了 2009 年 3 月至 2016 年 12 月在 2 家日本医院就诊的脆弱拟杆菌菌血症患者的病历。
我们共确定了 168 例脆弱拟杆菌菌血症患者。34 例患者发生菌血症复发。100 天内复发性菌血症的累积发生率为 18.7%。在单因素分析中,与复发性菌血症相关的因素包括抗癌化疗(风险比[HR],3.75;95%置信区间[CI],1.86-7.58;P<0.001)、全身皮质类固醇(HR,3.79;95%CI,1.70-8.45;P=0.0011)和血液系统恶性肿瘤(HR,3.18;95%CI,1.64-6.19;P<0.001)。多因素分析表明,抗癌化疗(HR,2.47;95%CI,1.19-5.12;P=0.015)和全身皮质类固醇(HR,2.40;95%CI,1.03-5.61;P=0.044)是独立的危险因素。在 168 例患者中,47 例接受了 SDD。根据 Gray 检验,SDD 可能降低了复发率,但无统计学意义(HR,0.46;95%CI,0.18-1.18;P=0.11)。然而,在比例风险模型分析中,SDD 降低了复发率(HR,0.36;95%CI,0.13-1.00;P=0.050)。
脆弱拟杆菌菌血症的 100 天累积复发率为 18.7%。抗癌化疗和全身皮质类固醇是复发性菌血症的独立危险因素。SDD 是降低复发率的一种潜在策略。